22. A use of a compound represented by Formula I or a pharmaceutical acceptable salt thereof as defined in any one of claims 1 to 12, in the preparation of a medicament for stimulating interleukin-12 (IL-12) production by an osteoclast precursor cell wherein an increased IL-12 production is measurable in the osteoclast precursor cell.

23. A use of a compound represented by Formula I or a pharmaceutical acceptable salt thereof as defined in any one of claims 1 to 12, in the preparation of a medicament for reducing acid phosphatase activity in bone cells, wherein a reduced phosphatase activity is measurable in said bone cells.

24. A use fof a compound represented by Formula I or a pharmaceutical acceptable salt thereof as defined in any one of claims 1 to 12, in the preparation of a medicament for reducing expression and/or activity of receptor activator of NF-κB ligand/Osteoprotegerin ratio (RANKL /OPG ratio) in bone cells.

25. A use of a compound represented by Formula I or a pharmaceutical acceptable salt thereof as defined in any one of claims 1 to 12, for the preparation of a medicament for increasing collagen content in bone in a subject in need thereof.

26. A use of a compound represented by Formula I or a pharmaceutical acceptable salt thereof as defined in any one of claims 1 to 12, for the preparation of a medicament for stimulating bone formation and/or for stimulating bone remodeling and/or for stimulating the differentiation and mineralization of osteoblasts and/or for inhibiting bone resorption in a subject in need thereof.